SAN DIEGO, Jan. 30, 2018 /PRNewswire/ — Edico Genome, the leading secondary analysis solution provider for next-generation sequencing (NGS), today announced the expansion of its commercial leadership team with the appointment of Mike Harkins as vice president of sales and Katherine Atkinson as vice president of business development. The executives join Edico Genome from Thermo Fisher Scientific and Illumina, respectively, and will play instrumental roles in the continued global expansion of Edico Genome’s DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT platform.
Katherine Atkinson joins Edico Genome with more than two decades of life science experience. During her five-year tenure at Illumina, Katherine oversaw numerous divisions, including molecular biology/PCR products, Inside Sales and most recently Global Channel Partners. In her most recent position as Commercial Director of Global Channel Partners, Katherine developed a high-performing Channel Partners program from the ground up, encompassing more than 70 partners in more than 130 countries worldwide.
“Edico Genome has truly made a name for itself as an innovator in the NGS market, continuously raising the bar in terms of speed, accuracy and cost,” said Katherine. “As part of the Edico Genome team, I look forward to working alongside some of the brightest talent in the industry to expand our key partnerships and bring ultra-rapid NGS to all corners of the globe.”
Prior to joining Edico Genome, Mike Harkins served as vice president of global sales at Thermo Fisher Scientific, heading the bioproduction sales force. Mike joined Life Technologies in 2000 as a sales representative and held positions of increasing responsibility during his 18 years career at the company. During his tenure at Thermo Fisher Scientific, Mike oversaw and participated in numerous large-scale commercial integrations. During his career, Mike has led U.S. and global sales forces at numerous companies including Invitrogen, Life technologies and Thermo Fisher Scientific.
“Speed and cost barriers have traditionally posed a bottleneck on the widespread adoption of NGS, preventing this potentially life-changing technology from reaching the masses,” said Mike. “I’m proud to be part of such an innovative team that is tearing down these barriers and replacing them with cross-industry collaborations and partnerships, enabling organizations of all shapes and sizes to enhance their work with NGS.”
Both Mike and Katherine will reside in Edico Genome’s new San Diego headquarters in Del Mar. Edico Genome plans to further expand its engineering and business development teams. View new positions at http://edicogenome.com/company/careers.
About Edico Genome
Edico Genome is the leading secondary analysis solution provider for next-generation sequencing, delivering its powerful DRAGEN Bio-IT platform to clinical, research and genome centers around the globe. Leveraging field programmable gate array (FPGA) technology, DRAGEN delivers best-in-class accuracy, speeds, scalability and costs, enabling customers of all sizes to focus on what matters most – delivering breakthrough results. The comprehensive set of DRAGEN pipelines can be run onsite, in the Cloud or through a seamless hybrid cloud blend, allowing organizations to scale as their throughput fluctuates. Edico Genome has set two GUINNESS WORLD RECORDSTM titles for its speed, and received top marks for its accuracy in the recent PrecisionFDA Challenge. For more information about DRAGEN, visit www.edicogenome.com.